12/30/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Ondansetron Teva

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Ondansetron

Ondansetron

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Kaplan YC, Richardson JL, Keskin-Arslan E, Erol-Coskun H, Kennedy D. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis. Reprod Toxicol. 2019;86:1-13.

  2. Huybrechts KF, Hernández-Díaz S, Straub L, Gray KJ, Zhu Y, Patorno E et al. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA. 2018;320(23):2429-2437.

  3. Pasternak B, Svanström H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368:814-23.

  4. Parker SE, Van Bennekom C, Anderka M, Mitchell AA, National Birth Defects Prevention Study. Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. Obstet Gynecol. 2018;132(2):385-394.

  5. Zambelli-Weiner A, Via C, Yuen M, Weiner DJ, Kirby RS. First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol. 2019;83:14-20.

  6. Danielsson B, Wikner BN, Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 2014;50:134-7.

  7. Andersen JT, et al. Ondansetron Use in Early Pregnancy and the Risk of Congenital Malformations – A Register Based Nationwide Cohort Study. International Society of Pharmaco-Epidemiology. Montreal, Canada; 2013. Abstract.

  8. Lemon LS, Bodnar LM, Garrard W, Venkataramanan R, Platt RW, Marroquin OC et al. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. Int J Epidemiol. 2019;0(0):0.

  1. Kaplan YC, Richardson JL, Keskin-Arslan E, Erol-Coskun H, Kennedy D. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis. Reprod Toxicol. 2019;86:1-13.
  2. Huybrechts KF, Hernández-Díaz S, Straub L, Gray KJ, Zhu Y, Patorno E et al. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA. 2018;320(23):2429-2437.
  3. Pasternak B, Svanström H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368:814-23.
  4. Parker SE, Van Bennekom C, Anderka M, Mitchell AA, National Birth Defects Prevention Study. Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. Obstet Gynecol. 2018;132(2):385-394.
  5. Zambelli-Weiner A, Via C, Yuen M, Weiner DJ, Kirby RS. First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol. 2019;83:14-20.
  6. Danielsson B, Wikner BN, Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 2014;50:134-7.
  7. Andersen JT, et al. Ondansetron Use in Early Pregnancy and the Risk of Congenital Malformations – A Register Based Nationwide Cohort Study. International Society of Pharmaco-Epidemiology. Montreal, Canada; 2013. Abstract.
  8. Lemon LS, Bodnar LM, Garrard W, Venkataramanan R, Platt RW, Marroquin OC et al. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. Int J Epidemiol. 2019;0(0):0.